On 3–8 June 2022, the First International Aegean Conference on Mesenchymal Cells in Health & Disease took place in Chania, Crete, and brought together clinicians and scientists who work on mesenchymal or stromal cell biology across different fields including immunity, inflammation and cancer.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
ANKRD1 is a mesenchymal-specific driver of cancer-associated fibroblast activation bridging androgen receptor loss to AP-1 activation
Nature Communications Open Access 03 February 2024
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Koliaraki, V., Prados, A., Armaka, M. & Kollias, G. Nat. Immunol. 21, 974–982 (2020).
Davidson, S. et al. Nat. Rev. Immunol. 21, 704–717 (2021).
Lütge, M., Pikor, N. B. & Ludewig, B. Immunol. Rev. 302, 32–46 (2021).
Korsunsky, I. et al. Med. (N Y) 3, 481–518.e414 (2022).
Chen, Y., McAndrews, K. M. & Kalluri, R. Nat. Rev. Clin. Oncol. 18, 792–804 (2021).
Biffi, G. et al. Cancer Discov. 9, 282–301 (2019).
Armaka, M. et al. J. Exp. Med. 205, 331–337 (2008).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Koliaraki, V., Dotto, GP., Buckley, C.D. et al. Mesenchymal cells in health and disease. Nat Immunol 23, 1395–1398 (2022). https://doi.org/10.1038/s41590-022-01318-8
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41590-022-01318-8
This article is cited by
-
ANKRD1 is a mesenchymal-specific driver of cancer-associated fibroblast activation bridging androgen receptor loss to AP-1 activation
Nature Communications (2024)
-
Post-transcriptional checkpoints in autoimmunity
Nature Reviews Rheumatology (2023)